Led · Series A · May 2025

PHASE Scientific builds urine-based liquid biopsy diagnostics around its PHASIFY™ urine concentration technology, which the company says captures approximately 10 times more target analytes than current gold standards. The firm is advancing a pipeline of non-invasive tests for early detection of multiple cancers, women's health conditions, and infectious diseases, and plans to expand R&D and commercialization. PHASE has commercialized over 30 diagnostic products, distributed more than 100 million tests in over 30 countries, and conducted over 8 million laboratory tests worldwide. It developed the world's first urine-based HPV test, which demonstrated 93.4% sensitivity for CIN2+ and over 97% concordance with Roche's Cobas 4800 for HPV16/18 in a clinical study with Peking University Shenzhen Hospital; the work received the Thomas V. Sedlacek Prize and conference recognition. The company intends to use recent funding to accelerate development and market rollout of next-generation urine-based diagnostics. Founded in 2015, PHASE is headquartered in Hong Kong SAR with cross-border operations in Southern California and China's Greater Bay Area.

Led · Series E · Mar 2025

Insilico Medicine develops Pharma.AI, a generative AI platform that spans biology, generative chemistry, clinical medicine and research and integrates LLM-powered engines such as Nach01 and Dora. The company operates Life Star1, a fully robotic lab that includes a bipedal humanoid AI Scientist to automate and optimize research workflows. Insilico has built a wholly-owned discovery portfolio of 30 assets, with 10 assets having received IND clearance, and its lead candidate Rentosertib has completed a Phase IIa trial showing favorable safety and a dose-dependent FVC response. The company reports it can nominate preclinical candidates in 12–18 months and synthesize/test 60–200 molecules per program, reflecting accelerated early-stage discovery. Insilico also generates sustainable revenue through out-licensing agreements (collectively valued at over $2.1 billion) and collaborations (collected value over $1.4 billion), with milestone payments contributing to financial performance. Future plans announced include refining AI models and algorithms, expanding and updating its automated lab, advancing clinical validation of its flagship IPF candidate, and accelerating other in-house and co-developed pipelines. Insilico Medicine is a clinical-stage, end-to-end AI-driven drug discovery company led by founder and CEO Alex Zhavoronkov. The company develops AI platforms that connect biology, chemistry, and clinical-trials analysis using deep generative models, reinforcement learning, transformers, and other machine-learning techniques. Its platforms are used to discover novel targets and design molecular structures with desired properties across oncology, fibrosis, immunity, central nervous system, and aging-related diseases. Insilico says it will use the new funding to accelerate its internal programs and to apply its platform to uncover more novel therapeutics. The company recently announced promising preclinical candidates for COVID-19 (and related variants) and for ALS. Insilico is headquartered in Hong Kong and sources R&D and management resources across the USA, Belgium, Russia, the UK, Taiwan, and China. Insilico Medicine builds an AI-driven drug discovery platform that identifies new targets and molecules and also develops its own therapeutics across fibrosis, immunology, oncology and CNS. The company began as a discovery-focused business and, since 2019, has been advancing in-house drug programs, nominating eight preclinical candidates since 2021. It generates revenue from R&D collaborations (including upfronts and milestones) and customer subscriptions to its platform. Insilico is in the R&D stage, is not yet profitable, and employs about 200 people across six countries and regions. The firm plans to use new capital to fund Phase I studies, further develop its AI platform, and pursue global expansion and strategic initiatives such as a robotic drug discovery laboratory and a robotic biological data factory. A prototype robotic lab is planned for Suzhou and will include AGVs and a phenotyping partnership with X-Imaging. Insilico Medicine operates AI platforms (PandaOmics for target discovery and Chemistry42 for molecule design) to accelerate drug discovery and reduce guesswork in target-to-molecule development. The company demonstrated a proof-of-concept by identifying a novel target for idiopathic pulmonary fibrosis and designing a candidate that progressed through animal studies. That IPF project condensed preclinical development to about 18 months at a cost of roughly $2.6 million, and Insilico says it has 16 therapeutic assets across programs. The company is filing an investigational new drug (IND) application with the FDA, plans to begin human dosing this year, and aims to start a clinical trial late this year or early next year. Insilico has collaborated with Pfizer, Johnson & Johnson, Taisho Pharmaceuticals, and announced a new partnership with Teva to use PandaOmics. Insilico Medicine is a Hong Kong-based developer of next-generation AI for drug discovery that applies deep learning across the drug discovery and development process. Its core technologies include generative chemistry and target-identification platforms, and the company collaborates with biopharmaceutical firms using disease-relevant assays to validate solutions and generate machine-learnable data. Insilico has identified promising targets across cancer, fibrosis, NASH, immunology and CNS. The company completed a $37M Series B financing to support commercialization and pipeline advancement. It plans to use the funds to commercialize its validated generative chemistry and target-identification technology, build a senior management team with pharmaceutical experience, and further develop and partner on specific therapeutic programs.